NEW YORK – Infectious disease molecular diagnostics developer DeepUll announced Tuesday that it has closed an oversubscribed €50 million ($57.0 million) Series C financing round.

纽约——传染病分子诊断开发商DeepUll周二宣布，已完成一轮超额认购的5000万欧元（5700万美元）C轮融资。

The round was co-led by Columbus Venture Partners, Panakès Partners, and Mérieux Equity Partners, with participation from existing investors Asabys Partners, Innvierte-CDTI, We Venture Capital, UI Investissement, Axis-ICO, Aliath Bioventures, and Kurma Partners.

本轮融资由哥伦布风险投资公司、帕纳克斯合伙人公司和梅里厄股权投资公司共同领投，现有投资者阿萨比斯合伙人公司、英维特-CDTI、我们风险资本、UI投资公司、Axis-ICO、阿里亚斯生物风险投资公司和库尔马合伙人公司也参与其中。

The new financing will accelerate commercialization of the Barcelona, Spain-based firm's automated PCR-based benchtop

新融资将加速这家位于西班牙巴塞罗那的公司基于自动化的PCR台式设备的商业化进程。

UllCore

乌尔核心

system that identifies sepsis-causing pathogens directly from blood. Specifically, the proceeds will be used to finalize clinical validation and expedite the regulatory process, DeepUll said.

直接从血液中识别败血症致病菌的系统。DeepUll 表示，这笔资金将用于完成临床验证并加快监管进程。

UllCore uses multiplex PCR targeting 95 percent of sepsis-causing pathogens, including bacteria and fungi, as well as antibiotic resistance genes. The test extracts total microbial DNA from 8 ml of whole blood and provides 52 reportable results.

UllCore 使用多重 PCR 检测技术，覆盖 95% 的败血症致病病原体，包括细菌和真菌，以及抗生素耐药基因。该测试从 8 毫升全血中提取总微生物 DNA，并提供 52 项可报告结果。

'This financing marks a critical step forward for DeepUll as we move towards completing the clinical studies of our diagnostic system,' DeepUll CEO Jordi Carrera said in a statement.

“这笔融资标志着DeepUll在完成我们诊断系统的临床研究方面迈出了关键一步，”DeepUll首席执行官乔迪·卡雷拉在一份声明中表示。

DeepUll's rapid pathogen identification and antimicrobial susceptibility testing system (

DeepUll的快速病原体鉴定和抗菌药物敏感性测试系统 (

ID/AST

身份证/天文学

) obtained

) 获得

breakthrough device designation

突破性设备指定

from the US Food and Drug Administration in December. The firm

来自美国食品和药物管理局，时间是十二月。该公司

raised €13 million

筹集了1300万欧元

in a Series B financing in 2022. It brought on

在 2022 年的 B 轮融资中，它带来了

Wade Stevenson

韦德·史蒂文森

, BioFire's former VP of clinical marketing for North America, last year as its chief marketing and sales officer.

，BioFire 北美临床营销前副总裁，去年担任其首席营销和销售官。